Effectiveness and Safety of Switching Rapid-Acting Insulins to Insulin Glulisine in Patients with Diabetes: The Observational IGLU-S Study.
Blood glucose
Diabetes
HbA1c
Hypoglycaemia
Insulin
Journal
Diabetes therapy : research, treatment and education of diabetes and related disorders
ISSN: 1869-6953
Titre abrégé: Diabetes Ther
Pays: United States
ID NLM: 101539025
Informations de publication
Date de publication:
Mar 2021
Mar 2021
Historique:
received:
12
11
2020
accepted:
06
01
2021
pubmed:
6
2
2021
medline:
6
2
2021
entrez:
5
2
2021
Statut:
ppublish
Résumé
The IGLU-S study assessed the effectiveness of insulin glulisine after switching from human insulin/other rapid-acting insulin analogues in patients with type 1 diabetes (T1DM) and type 2 diabetes (T2DM) in a real-world setting in Germany. Open-label, prospective, multicentre, non-interventional study in Germany. The primary outcome was proportion of patients reaching pre-defined glycosylated haemoglobin A1c (HbA1c) goal at 3, 6, 9 and 12 months. Secondary outcomes included absolute changes in HbA1c, rate of hypoglycaemia and 7-point blood glucose profiles. Overall, 432 (55 T1DM, 377 T2DM) patients were enrolled. Baseline HbA1c was 8.2% (T1DM) and 8.3% (T2DM); individual HbA1c targets were 6.8% and 6.9%, respectively. After insulin glulisine introduction, the proportion of patients achieving their individual HbA1c increased to 43.6% (T1DM) and 39.6% (T2DM) of patients at 12 months. At 12 months, mean HbA1c was reduced by 0.86 ± 1.03% (p < 0.0001) in T1DM and 1.01 ± 1.02 (p < 0.0001) in T2DM. The 7-point blood glucose profile showed a significant reduction in patients with T2DM (p< 0.0001) and a non-significant reduction in T1DM patients. Confirmed symptomatic hypoglycaemia was 5.7% (T1DM) and 1.6% (T2DM). There were no cases of severe hypoglycaemia. Switching prandial insulin to insulin glulisine resulted in improved effectiveness with 43.6% of T1DM and 39.6% of T2DM patients reaching their individual pre-defined HbA1c target within 1 year. Switching was safe and was associated with a low rate of hypoglycaemia and adverse events. https://awbdb.bfarm.de ; Identifier: 6818; Date of registration: 23.06.2016.
Identifiants
pubmed: 33544356
doi: 10.1007/s13300-021-00999-y
pii: 10.1007/s13300-021-00999-y
pmc: PMC7947079
doi:
Types de publication
Journal Article
Langues
eng
Pagination
749-764Références
Arnolds S, Rave K, Hovelmann U, Fischer A, Sert-Langeron C, Heise T. Insulin glulisine has a faster onset of action compared with insulin aspart in healthy volunteers. Exp Clin Endocrinol Diabetes. 2010;118(9):662–4.
doi: 10.1055/s-0030-1252067
Bolli GB, Luzio S, Marzotti S, Porcellati F, Sert-Langeron C, Charbonnel B, et al. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. Diabetes Obes Metab. 2011;13(3):251–7.
doi: 10.1111/j.1463-1326.2010.01343.x
Philotheou A, Arslanian S, Blatniczky L, Peterkova V, Souhami E, Danne T. Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes. Diabetes Technol Ther. 2011;13(3):327–34.
doi: 10.1089/dia.2010.0072
Böhm BO, Dreyer M, Fritsche A, Füchtenbusch M, Gölz S, Martin S. Therapie des Typ 1 diabetes. Diabetologie und Stoffwechsel. 2011;6:S105–206.
doi: 10.1055/s-0031-1283738
Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycemia in type 2 diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669–701.
doi: 10.2337/dci18-0033
Bando Y, Shima K, Aoki K, Kanehara H, Hisada A, Okafuji K, et al. Efficacy and safety of insulin glulisine in intensive insulin therapy: bolus insulin adjust nice control by apiDRA Study (BANDRA Study). SciRes J Diabetes Mellitus. 2015;5:28–35.
doi: 10.4236/jdm.2015.51004
Yanagisawa K, Ashihara J, Obara S, Wada N, Takeuchi M, Nishino Y, et al. Switching to multiple daily injection therapy with glulisine improves glycaemic control, vascular damage and treatment satisfaction in basal insulin glargine-injected diabetic patients. Diabetes Metab Res Rev. 2014;30(8):693–700.
doi: 10.1002/dmrr.2537
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus. Cochrane Database Syst Rev. 2016;6:CD012161.
Fullerton B, Siebenhofer A, Jeitler K, Horvath K, Semlitsch T, Berghold A, et al. Short-acting insulin analogues versus regular human insulin for adult, non-pregnant persons with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2018;12:CD013228.
pubmed: 30556900
Melo KFS, Bahia LR, Pasinato B, Porfirio GJM, Martimbianco AL, Riera R, et al. Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr. 2019;11:2.
doi: 10.1186/s13098-018-0397-3
Polonsky WH, Fisher L, Schikman CH, Hinnen DA, Parkin CG, Jelsovsky Z, et al. Structured self-monitoring of blood glucose significantly reduces A1C levels in poorly controlled, noninsulin-treated type 2 diabetes: results from the Structured Testing Program study. Diabetes Care. 2011;34(2):262–7.
doi: 10.2337/dc10-1732
Sieber J, Flacke F, Link M, Haug C, Freckmann G. Improved glycemic control in a patient group performing 7-point profile self-monitoring of blood glucose and intensive data documentation: an open-label, multicenter. Observational Study Diabetes Ther. 2017;8(5):1079–85.
doi: 10.1007/s13300-017-0306-z
Lak V, Svensson AM, Miftaraj M, Franzen S, Eliasson B. Clinical effects and safety of direct-acting insulin analogs in patients with type 1 diabetes: a Nation-wide observational cohort study. Diabetes Ther. 2016;7(3):561–73.
doi: 10.1007/s13300-016-0191-x